139 related articles for article (PubMed ID: 38073159)
21. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract][Full Text] [Related]
22. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
[TBL] [Abstract][Full Text] [Related]
24. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.
Kumar A; Cliby WA
Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415
[TBL] [Abstract][Full Text] [Related]
25. [Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].
Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
Gynecol Obstet Fertil Senol; 2021 Oct; 49(10):736-743. PubMed ID: 33636412
[TBL] [Abstract][Full Text] [Related]
26. Surgery for advanced epithelial ovarian cancer.
Hacker NF; Rao A
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():71-87. PubMed ID: 27884789
[TBL] [Abstract][Full Text] [Related]
27. CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.
Classe JM; Ferron G; Ouldamer L; Gauthier T; Emambux S; Gladieff L; Dupre PF; Anota A
Int J Gynecol Cancer; 2022 Aug; 32(8):1071-1075. PubMed ID: 35321888
[TBL] [Abstract][Full Text] [Related]
28. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
29. Update on the role of surgery in the management of advanced epithelial ovarian cancer.
Straubhar A; Chi DS; Long Roche K
Clin Adv Hematol Oncol; 2020 Nov; 18(11):723-731. PubMed ID: 33406064
[TBL] [Abstract][Full Text] [Related]
30. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
Liu J; Zhang K
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
[TBL] [Abstract][Full Text] [Related]
31. Novel Surgical Strategies in the Treatment of Gynecological Malignancies.
Angeles MA; Martínez-Gómez C; Migliorelli F; Voglimacci M; Figurelli J; Motton S; Tanguy Le Gac Y; Ferron G; Martinez A
Curr Treat Options Oncol; 2018 Nov; 19(12):73. PubMed ID: 30411170
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
33. Interval cytoreduction for advanced ovarian cancer: is minimally invasive surgery ready for the next prospective randomized trial?
Ramirez PT
Int J Gynecol Cancer; 2019 Jan; 29(1):3-4. PubMed ID: 30640675
[No Abstract] [Full Text] [Related]
34. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
[TBL] [Abstract][Full Text] [Related]
37. Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer.
Tsibulak I; Fotopoulou C
Int J Gynecol Cancer; 2023 Oct; 33(10):1627-1632. PubMed ID: 37553165
[TBL] [Abstract][Full Text] [Related]
38. Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back.
Gueli Alletti S; Vizzielli G; Lafuenti L; Costantini B; Fagotti A; Fedele C; Cianci S; Perrone E; Gallotta V; Rossitto C; Scambia G
J Minim Invasive Gynecol; 2018; 25(5):816-822. PubMed ID: 29269126
[TBL] [Abstract][Full Text] [Related]
39. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
Bailey CD; Previs R; Fellman BM; Zaid T; Huang M; Brown A; Enbaya A; Balakrishnan N; Broaddus RR; Bodurka DC; Soliman P; Fleming ND; Nick A; Sood AK; Westin SN
Int J Gynecol Cancer; 2021 Feb; 31(2):232-237. PubMed ID: 33122243
[TBL] [Abstract][Full Text] [Related]
40. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
